- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
February 25th, 2009
Financings Roundup Founded in late 2007 to develop a technology platform that combines discoveries in immunobiology with advances in nanotechnology, Selecta Biosciences Inc. is ready to start moving its program toward the clinic thanks to a $15.1 million Series B round.
"We were gratified to find a very receptive audience at a very difficult time," said Robert Bratzler, executive chairman of the Watertown, Mass.-based firm. He called the Series B "our first substantial round," following $2.5 million in seed funding in May 2008 from Polaris Venture Partners and Flagship Ventures.
Both of those investors returned for the Series B, joined by NanoDimension, a VC firm that focuses on nanotechnologies, and individual investor Timothy A. Springer, a professor of pathology at Harvard Medical School and previous founder of LeukoSite Inc., which was acquired by Millennium Pharmaceuticals Inc. in 1999.
|Related News Press|
News and information
Animal study shows flexible, dissolvable silicon device promising for brain monitoring: Other applications include post-operative observation for vascular, cardiac, and orthopaedic procedures, finds Penn study May 5th, 2016
Aspen Aerogels to Present at the 28th Annual ROTH Conference March 14th, 2016
Arrowhead to Present at Upcoming March Conferences March 1st, 2016
The intermediates in a chemical reaction photographed 'red-handed' Researchers at the UPV/EHU-University of the Basque Country have for the first time succeeded in imaging all the steps in a complex organic reaction and have resolved the mechanisms that explain it May 4th, 2016
Nuclear pores captured on film: Using an ultra fast-scanning atomic force microscope, researchers from the University of Basel have filmed 'living' nuclear pore complexes at work for the first time May 3rd, 2016